By Caitlin Forsyth
The Washington State Legislature convenes for its regular session next Monday, January 13. While our legislators will consider a multitude of issues important to the continued strength and health of the state, it will likely take up issues of special importance to Washington’s unique and fast-growing life sciences industry.
The Washington Biotechnology & Biomedical Association (WBBA) is a nonprofit trade association that serves Washington’s booming life sciences industry. Members of WBBA include organizations engaged in the research and development of life science technologies, including such well-known companies as BioRad and Amgen. WBBA’s mission is “to support and help to grow Washington State’s life science ecosystem.” One way WBBA accomplishes its mission is through legislative advocacy.
One of WBBA’s advocacy priorities for the upcoming legislative session is to convince state legislators to update Washington law to allow for the substitution of biosimilars for name-brand biologics, analogous to the common practice of substituting generics for name-brand chemical pharmaceuticals. Biologic drugs are large, complex molecules that pose unique patient safety issues that are not otherwise presented by chemical pharmaceuticals. The inherent complexity of biologics and their manufacture can create potential differences across biosimilar versions of the original product. Because of the differences in production as well as the unique cellular source of these drugs, it is nearly impossible to make truly identical copies of a protein using two different cell production lines. This makes both originator and biosimilar biologic drug production much more challenging than small molecular, generic chemical drug production.




